UK review of allergy services welcomed

13 August 2006

A UK government review of services for allergy has been welcomed by Allergy Therapeutics, a specialist drug firm focused on allergy vaccination. The report by the Department of Health found that patients "can wait three to nine months for an appointment to see a consultant in secondary care." The firm believes that recognition of a problem must be backed up with "a program of action."

In a statement, Allergy Therapeutics noted the "almost total lack of specialist heath care infrastructure for allergy sufferers in the UK." One consequence of this, the firm says, is the absence of allergy vaccination, which is available in other European Union countries.

However, a spokesman for the British Society for Allergy and Clinical Immunology told the BBC, the UK's public broadcaster: "the Department of Health recognizes that there is a problem, but fails to adequately address this and fails to make any recommendation that will ensure change."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight